Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.69 |
| ▸ | IL1RN | P18510 | 1/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756876 | 0.89 | PGR (1.00) | PGRCYP19A1IL1RNKEAP1ERAP1 | |
| SCHEMBL9001184 | 0.87 | KEAP1 (0.79) | PGRCYP19A1IL1RNKEAP1ERAP1 | |
| SCHEMBL2444333 | 0.85 | KEAP1 (0.64) | PGRCYP19A1IL1RNKEAP1ERAP1 | |
| SCHEMBL3789469 | 0.85 | KEAP1 (0.64) | PGRCYP19A1IL1RNKEAP1ERAP1 | |
| SCHEMBL343776 | 0.85 | HTR6 (0.73) | PGRCYP19A1KEAP1HTR6ALOX15 | |
| SCHEMBL14937571 | 0.85 | PGR (0.72) | PGRCYP19A1ALOX15ALDH1A1PKM | |
| SCHEMBL29953442 | 0.84 | CYP19A1 (0.62) | PGRCYP19A1ALOX15ALDH1A1PKM | |
| SCHEMBL15208759 | 0.84 | CYP19A1 (0.62) | PGRCYP19A1ALOX15ALDH1A1PKM | |
| SCHEMBL664321 | 0.84 | KMT2A (0.75) | PGRCYP19A1ALOX15ALDH1A1PKM | |
| SCHEMBL29561272 | 0.83 | PGR (0.67) | PGRCYP19A1ALOX15ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| EP-0104353-B1 | HEAT SENSITIVE RECORD MATERIAL | HODOGAYA CHEMICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| US-4482905-A | FLUORAN, BENZENESULFONAMIDE, ACID, BINDER | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-11-13 | — | — | US | claimed |
| EP-0104353-A2 | Heat sensitive record material | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-04-04 | — | — | EP | claimed |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| CN-114163362-B | Preparation method of N-benzenesulfonyl-4-halo-2-nitroaniline | 山东第一医科大学(山东省医学科学院) | 2023-04-07 | — | — | CN | disclosed |
| CN-114163362-A | Preparation method of N-benzenesulfonyl-4-halo-2-nitroaniline | 山东第一医科大学(山东省医学科学院) | 2022-03-11 | — | — | CN | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| CN-100536839-C | Urea derivatives as integrin alpha 4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2009-09-09 | — | — | CN | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | LABORATORIOS ALMIRALL, S.A. | 2007-10-11 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| CN-1531425-A | Urea derivatives as integrin alpha 4 antagonists | ������ҩ������˾ | 2004-09-22 | — | — | CN | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1383750-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002078970-A1 | HEAT SENSITIVE RECORDING MATERIAL | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | PGR 598/4885CYP19A1 176/4885IL1RN 4803/4885 |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | PGR 1895/4885CYP19A1 4838/4885IL1RN 172/4885 |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | PGR 3961/4885CYP19A1 3254/4885IL1RN 3494/4885 |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | ITGB4, ITGA4, ITGB7 | PGR 3910/4885CYP19A1 4860/4885IL1RN 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.